Seminars in Oncology
Volume 36, Issue 3 , Pages 237-249 , June 2009

Breast Cancer Before Age 40 Years

  • Carey K. Anders

      Affiliations

    • University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
    • Corresponding Author InformationAddress correspondence to Carey K. Anders, MD, Assistant Professor, Hematology-Oncology, University of North Carolina at Chapel Hill, 170 Manning Dr, POB 3119, Campus Box 7305, Chapel Hill, NC 27599-7305
    • ,
  • Rebecca Johnson

      Affiliations

    • Seattle Children's Hospital, Seattle, WA
    • ,
  • Jennifer Litton

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Marianne Phillips

      Affiliations

    • Princess Margaret Hospital for Children, Perth, Australia
    • ,
  • Archie Bleyer

      Affiliations

    • St. Charles Medical Center, Bend, OR

References 

  1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008;based on November 2007 SEER data submission, posted to the SEER website http://seercancergov/csr/1975_2005/,
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  3. Ravdin P, Conrin K, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–1674
  4. Althius M, Brogan D. Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003;14:151–160
  5. Donovan M, Tiwary C, Axelrod D. Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk. Med Hypoth. 2007;68:756–766
  6. Shavers VH, Harlan LC, Stevens J. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:134–147
  7. Weir HK, Jim MA, Marrett LD, Fairley T. Cancer in American Indian and Alaska Native young adults (ages 20-44 years): US, 1999-2004. Cancer. 2008;113(Suppl):1153–1167
  8. Baquet C, Mishra S, Commiskey P, Ellison G, DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2008;100:480–488
  9. Clegg L, Reichman M, Miller B, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. Nov 12, 2008;[Epub ahead of print]
  10. Wingo P, King J, Swan J, et al. Breast cancer incidence among American Indian and Alaska Native women: US, 1999-2004. Cancer. 2008;113:1191–1202
  11. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130
  12. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006;42:1143–1150
  13. Bleyer A, O'Leary M, Barr R, Ries L. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH Publication No. 06-5767. Bethesda, MD: National Cancer Institute; 2006;
  14. Silvera S, Jain M, Howe G, Miller A, Rohan T. Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat. 2006;97:97–106
  15. Rodriguez A, Chew H, Cress R, et al. Evidence of poorer survival in pregnancy-associated breast cancer. Obstet Gynecol. 2008;112:71–78
  16. Cho E, Chen W, Hunter D, et al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med. 2006;166:2253–2259
  17. Do M, Lee S, Kim J, Jung P, Lee M. Fruits, vegetables, soy foods and breast cancer in pre- and postmenopausal Korean women: a case-control study. Int J Vitam Nutr Res. 2007;77:130–141
  18. Slattery M, Edwards S, Murtaugh M, et al. Physical activity and breast cancer risk among women in the southwestern United States. Ann Epidemiol. 2007;17:342–353
  19. McCormack V, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1159–1169
  20. Bérubé S, Diorio C, Brisson J. Regular use of multivitamin-multimineral supplements may be associated with higher mean breast density among premenopausal women. Am J Clin Nutr. 2008;87:1400–1404
  21. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:1696–1701
  22. Johnson E. Breast cancer racial differences before age 40—implications for screening. J Nat Med Assoc. 2002;94:149–156
  23. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer. 2007;59:54–61
  24. Braverman A. Evidence that high calcium and vitamin D intake decrease the risk of breast cancer in premenopausal women: implications for breast cancer prevention and screening. South Med J. 2007;100:1061–1062
  25. Lin J, Manson J, Lee I, Cook N, Buring J, Zhang S. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007;167:1050–1059
  26. Bérubé S, Diorio C, Mâsse B, et al. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2005;14:1653–1659
  27. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis and breast cancer. N Engl J Med. 1986;315:559–563
  28. El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194
  29. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 1997;33:425–428
  30. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273–279
  31. Anders C, Hsu D, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324–3330
  32. Albain KS, Allred DC, Clark GM. Breast cancer outcomes and predictors of outcome: are there age differentials?. J Natl Cancer Inst Monogr. 1994;16:35–42
  33. Kollias J, Elston CW, Ellis I, et al. Early onset breast cancer—histopathological and prognostic considerations. Br J Cancer. 1997;75:1318–1323
  34. de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341:1039–1043
  35. Nixon AJ, Neuburg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I and II breast cancer. J Clin Oncol. 1994;12:888–894
  36. Gnerlich J, Deshpande A, Jeffe D, Sweet A, White N, Margenthaler J. Elevated breast cancer mortality in young women (<40 yrs) compared with older women is attributed to poorer survival in early stage disease. J Clin Oncol. 2008;2008 American College of Surgeons Clinical Congress
  37. Margenthaler J. Younger women diagnosed with early-stage breast cancer more likely to die than older women. San Francisco, CA: American College of Surgeons Clinical Congress; October 12-16, 2008;
  38. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113;:357–370
  39. Shannon C, Smith I. Breast cancer in adolescents and young women. Eur J Cancer. 2003;39:2632–2642
  40. Kurtz J, Jacquemier J, Amalric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients?. J Clin Oncol. 1990;8:591–598
  41. Voogd A, Nielsen M, Peterse J, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–1697
  42. Goldhirsch A, Glick J, Gelber R, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer (Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer). J Clin Oncol. 2001;19:3817–3827
  43. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000;355:1869–1874
  44. Kroman N, Jensen M, Wohlfahrt J, Mouridsen H, Andersen P, Melbye J. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000;320:474–478
  45. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D (Anderson Cancer Center experience). Cancer. 2001;92:2523–2528
  46. Levine M, Bramwell V, Pritchard K, et al. National Cancer Institute of Canada Clinical Trials Group Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol. 1998;16:2651–2658
  47. EBCTG. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942
  48. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  49. Henderson I, Berry D, Demetri G, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  50. Mamounas E, Lembersky B, Fisher B, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–3696
  51. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  52. Citron M, Berry D, Cirroncione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21:1431–1439
  53. Bianco A, Del Mastro L, Gallo C, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991;63:799–803
  54. Goldhirsch A, Gelber R, Castiglione M The International Breast Cancer Study Group. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol. 1990;1:183–188
  55. Jonat W, Kaufmann M, Sauerbrei W, et al. The Zoladex Early Breast Cancer Research Association Study Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. J Clin Oncol. 2002;20:4628–4635
  56. Richards M, O'Reilly S, Howell A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol. 1990;8:2032–2039
  57. Goodwin P, Ennis M, Pritchard K, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–2370
  58. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000;18:2718–2727
  59. Davidson NE, N'Neill AM, Vukov AM, et al. Chemo-endocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E 5188). J Clin Oncol. 2005;23:5973–5982
  60. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol. 2002;20:4621–4627
  61. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nature Rev Cancer. 2008;8:288–298
  62. Newman L, Bunner S, Carolin K, et al. Ethnicity related differences in the survival of young breast carcinoma patients. Cancer. 2002;95:21–27
  63. De Jesus MA, Fujita M, Kim KS, Goldson AL. Retrospective analysis of breast cancer among young African American females. Breast Cancer Res Treat. 2003;78:81–87
  64. Biffl W, Myers A, Franciose R. Is breast cancer in young Latinas a different disease?. Am J Surg. 2001;182:596–600
  65. Foo C, Su D, Chong C. Breast cancer in young Asian women: study on survival. Aust N Z J Surg. 2005;75:566–572
  66. Lee K, Chen S, Chan C, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev. 2008;17:2647–2655
  67. Hooning M, Aleman B, Hauptmann M, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008;26:5561–5568
  68. Lee S, Schover L, Partridge A, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–2931
  69. Partridge A, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–4783
  70. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90:1635–1639
  71. Ismail-Khan R, Minton S, Cox C, Sims I, Lacevic M, Gross-King M. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy [abstract 524]. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008;26:15S
  72. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630–2635
  73. Smith L, Dalrymple J, Leiserowitz G, Danielsen B, Gilbert W. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol. 2001;184:1504–1512
  74. Anderson B, Petrek J, Byrd D, Senie R, Borgen P. Pregnancy influences breast cancer stage at diagnosis in women 30 years of age or younger. Ann Surg Oncol. 1996;3:204–211
  75. Noyes R, Spanos W, Montague E. Breast cancer in women aged 30 and under. Cancer. 1982;49:1302–1307
  76. Mueller B, Simon M. Childbearing and survival after breast carcinoma in young women. Cancer Causes Control. 2003;98:1131–1140
  77. Byrd B, Bayer D, Robertson J, Stephenson S. Treatment of breast tumors associated with pregnancy and lactation. Ann Surg. 1962;155:940–947
  78. Samuels T, Liu F, Yaffe M, Haider M. Gestational breast cancer. Can Assoc Radiol J. 1998;49:172–180
  79. Yang WT, Dryden MJ, Gwyn K, Whitman GJ, Theriault R. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology. 2006;239:52–60
  80. Loibl S, Minckwitz GV, Gwyn K, et al. Breast carcinoma during pregnancy. Cancer. 2006;106:237–246
  81. Hahn K, Johnson P, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107:1219–1226
  82. Mir O, Berveiller P, Ropert S, et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol. 2008;19:607–613
  83. Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Trastuzumab treatment for breast cancer during pregnancy. Can Fam Phys. 2008;54:31–32
  84. Bonnier P, Romain S, Dilhuydy J, et al. Influence of pregnancy on the outcome of breast cancer: a case-control study. Int J Cancer. 1997;72:720–727
  85. Kalder M, Hadji P. Bone health in postmenopausal women (PMW) with hormone-sensitive breast cancer (HSBC) receiving adjuvant aromatase inhibitor (AI) therapy [abstract 11556]. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008;26:15S
  86. Shapiro CL, Halabi S, Gibson G, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809 [abstract 512]. J Clin Oncol. 2008;26:15S;ASCO Annual Meeting Proceedings (Post-Meeting Edition)
  87. Hershman D, McMahon D, Crew K, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26:4739–4745
  88. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [abstract LBA4]. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008;26:15S
  89. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840–849
  90. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–1399
  91. Peto J, Mack T. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000;26:411–414
  92. Li F, Fraumeni J. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? (Ann Intern Med). 1969;71:747–752
  93. Nelen M, Padberg G, Peeters E, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet. 1996;13:114–146
  94. Ford D, Easton D, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families (The Breast Cancer Linkage Consortium). Am J Hum Genet. 1998;62:676–689
  95. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–1333
  96. Saslow D, Boetes C, Burke W, et al. American Cancer Society Guidelines for breast screening with mri as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89
  97. Vogel V, Costantino J, Wickerham D, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–2741
  98. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;9018:1371–1388
  99. King M, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–2256
  100. Schain W, d'Angelo T, Dunn M, Lichter A, Pierce L. Mastectomy versus conservative surgery and radiation therapy (Psychosocial consequences). Cancer. 1994;73:1221–1228
  101. Ganz P, Greendale G, Petersen L, Kahn B, Bower J. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184–4193
  102. Phillips K, Osborne R, Giles G, et al. Psychosocial factors and survival of young women with breast cancer: a population-based prospective cohort study. J Clin Oncol. 2008;26:4666–4671

PII: S0093-7754(09)00037-2

doi: 10.1053/j.seminoncol.2009.03.001

Seminars in Oncology
Volume 36, Issue 3 , Pages 237-249 , June 2009

Article Tools

* Image Usage & Resolution